Stellate Ganglion Phototherapy Using a Portable Radiation Device, for Destination Therapy of Drug-Refractory Ventricular Tachycardia

Several studies have demonstrated the efficacy of stellate ganglion phototherapy (SGP) for drug-refractory ventricular arrhythmia (VA), primarily as a temporary or adjunctive measure prior to antiarrhythmic titration, ablation, surgical sympathectomy, and heart transplantation.1,2 SGP employs near-infrared light to target the cervical region, presents a less invasive alternative to surgical interventions, and is expected to become a destination therapy for outpatients. However, the long-term efficacy and frequency-dependent effects of portable SGP devices remain unclear.